A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults

What Was Tested

In this not phased trial, researchers set out to test NAD+.

The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo?

It had two arms (groups): NAD+ (experimental) and Placebo (placebo comparator).

Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.

Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.

The registry classes the interventions as dietary supplement.

Who Took Part

80 planned participants were the target.

It was open to people of any sex aged from 40 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Males and females between 40 and 65 years of age, inclusive, at screening. Body Mass Index (BMI) between 18.5 and 29.9 kg/m2. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System). Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s). Vasectomy of partner at least 6 months prior to screening.

The full record lists 16 inclusion and 24 exclusion criteria; among the exclusions: individuals who are pregnant, breast feeding, or planning to become pregnant during the study; unstable metabolic disease or chronic diseases as assessed by the qi; individuals with an autoimmune disease or are immune compromised as assessed by the qi.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

The NAD+ group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-08 with completion listed for 2027-03.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo (time frame: Day 0 to 56).

It also tracked 7 secondary outcomes, for example Change in NAD+ levels in whole blood from baseline to days 14 and 28 between the NAD+ supplement and placebo, Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in Cognitive function, Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in appearance and aesthetics, Change from baseline to day 56 between the NAD+ supplement and placebo in energy and metabolism, Change from baseline to day 56 between the NAD+ supplement and placebo in cellular health and longevity and Change from baseline to day 56 between the NAD+ supplement and placebo in oxidative stress.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 80 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.